Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Growblox Sciences, Inc. Acquires Two Additional Medical Cannabis Cultivation And Production Establishment Licenses In The State Of Nevada
LAS VEGAS, Oct. 4, 2016 /PRNewswire/ -- Growblox Sciences, Inc. (OTCQB: GBLX) announces today that it has acquired two additional Medical Marijuana Establishment ("MME") licenses in Clark County, Nevada. Growblox has formed GB Sciences Las Vegas, LLC. in order to acquire these two licenses. Growblox will be the owner/operator of the businesses and own 60% of the entity with the option to own up to 80%.
The production license will be incorporated into our cannabis cultivation facility in Las Vegas, NV. This license will allow Growblox to convert plants to oil, which opens a vast market that utilizes more of the plant, and produces a higher profit margin. These oils can then be used to make many popular products, such as personal vaporizer pens, gel caps, edibles, a large number of beauty aids, cosmetics, pure botanicals, extracts, and much more.
The cultivation license expands our current Nevada cultivation capacity well beyond the current capacity of 28,000 sq ft, which can support, 4000 plants, with a 20 million dollar run rate at full production.
"I am extremely pleased to see our hard work come to fruition. These cultivation and production licenses will position us to offer a highly diverse suite of products for patients from all medical cannabis-approved states, due to Nevada's critical reciprocity regulation. This will also enhance Growblox's positioning as a fully vertically-integrated and formidable presence in the Nevada Medical Cannabis Market," stated John Poss, Growblox CEO.
About Growblox Sciences, Inc.
Growblox Sciences, Inc. (GBLX) is a diverse vertically integrated cannabis company, focused on cultivation as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about Growblox Sciences, Inc., go to: http://growblox.com
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
Corporate:
Growblox Sciences, Inc.,
3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Liz Bianco Publicity Director, liz@gbsciences.com, http://growblox.com
Investors: John Poss, j.poss@gbsciences.com
SOURCE Growblox Sciences, Inc.
Related Links
http://www.growblox.com
Growblox Sciences, Inc. Acquires Two Additional Medical Cannabis Cultivation And Production Establishment Licenses In The State Of Nevada
LAS VEGAS, Oct. 4, 2016 /PRNewswire/ -- Growblox Sciences, Inc. (OTCQB: GBLX) announces today that it has acquired two additional Medical Marijuana Establishment ("MME") licenses in Clark County, Nevada. Growblox has formed GB Sciences Las Vegas, LLC. in order to acquire these two licenses. Growblox will be the owner/operator of the businesses and own 60% of the entity with the option to own up to 80%.
The production license will be incorporated into our cannabis cultivation facility in Las Vegas, NV. This license will allow Growblox to convert plants to oil, which opens a vast market that utilizes more of the plant, and produces a higher profit margin. These oils can then be used to make many popular products, such as personal vaporizer pens, gel caps, edibles, a large number of beauty aids, cosmetics, pure botanicals, extracts, and much more.
The cultivation license expands our current Nevada cultivation capacity well beyond the current capacity of 28,000 sq ft, which can support, 4000 plants, with a 20 million dollar run rate at full production.
"I am extremely pleased to see our hard work come to fruition. These cultivation and production licenses will position us to offer a highly diverse suite of products for patients from all medical cannabis-approved states, due to Nevada's critical reciprocity regulation. This will also enhance Growblox's positioning as a fully vertically-integrated and formidable presence in the Nevada Medical Cannabis Market," stated John Poss, Growblox CEO.
About Growblox Sciences, Inc.
Growblox Sciences, Inc. (GBLX) is a diverse vertically integrated cannabis company, focused on cultivation as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about Growblox Sciences, Inc., go to: http://growblox.com
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
Corporate:
Growblox Sciences, Inc.,
3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Liz Bianco Publicity Director, liz@gbsciences.com, http://growblox.com
Investors: John Poss, j.poss@gbsciences.com
SOURCE Growblox Sciences, Inc.
Related Links
http://www.growblox.com
GrowBLOX Sciences, Inc. Announces Exclusive Rights To Kyle Kushman's Cannabis Brands, Strains And Genetics In The State Of Nevada
LAS VEGAS, June 7, 2016 /PRNewswire/ -- GrowBLOX Sciences, Inc. (OTCQB: GBLX) announces the execution of an agreement with Kyle Kushman, Kushman Brands and Genetics LLC, and its affiliate Karma Consulting (collectively, "Kushman"). Pursuant to the agreement, GrowBLOX and its subsidiary GB Sciences Nevada, LLC (dba "Cultivation Labs") will have exclusive rights in Nevada to Kushman's cannabis brands, strains and genetics. Kushman also will advise GB Sciences' Cultivation Labs on the expansion of its cannabis cultivation facility in Las Vegas, as well as operating processes and procedures based on Kushman's methods and unique Veganic growing techniques.
Kyle Kushman (http://kylekushman.com/) is one of the most well-known and award winning cannabis cultivators in the world. He has won 13 Cannabis Cup High Times awards, the "Oscar" of the Cannabis industry. Kyle brings all of his diverse and award-winning strains to GB Sciences' Cultivation Labs, including Strawberry Cough, Cherry Cough, Adonai OG, Silverback Grape Ape, Starberry, KK Stardawg and Jurassic Haze strains. Kyle's Veganic method of growing has been described as the next step in "organic" cultivation and has been shown to produce some of the cleanest and most efficacious cannabis in the marketplace.
GrowBLOX Founder and Chief Innovation Officer, Craig Ellins said, "The cannabis world knows about the amazing marijuana products created by Kyle Kushman, particularly his 'Vegamatrix' line of vegan and organic nutrients – the only nutrients capable of nurturing the cleanest and purest cannabis possible. When one combines Kushman's 30 years of experience and expertise and demonstrably superior nutrients with our innovative tissue culturing technology, the result can only be the best and most consistent pesticide free, natural medical marijuana products ever produced from the cannabis plant."
GrowBLOX CEO, John Poss said, "This is a major win for medical marijuana patients in Nevada and a homerun for our shareholders. The exclusive on his brands together with his cultivation design expertise and his Vegamatrix nutrients will clearly give us a competitive advantage in Nevada. The eight strains he brings will complement perfectly the over 20 strains that GB Sciences has developed to offer a wide variety of treatment options to marijuana patients. This deal positions us perfectly in the medical cannabis market, but also gives us a strong position in the soon to come recreational market, which is expected to be created by a proposition vote in November of this year."
Kushman said, "I feel that my expertise paired with the labs and systems put in place by GrowBLOX is a dream come true. Using artisanal techniques to take medical cannabis to its highest level, we are going to produce the highest quality Veganic cannabis for Nevada medical marijuana patients."
GrowBLOX Chief Science Officer, Dr. Andrea Small-Howard, said, "The Kushman brands and genetics are among the best-known in the world among both personal and commercial growers of the cannabis plant. Growing Kushman strains in our Cultivation Labs facility in Las Vegas and using their proven cultivation methods should ensure the superior productivity, high potency and clean test results afforded by the organic nutrients in the Vegamatrix line."
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc. (GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. The Company has leading technology and cannabis industry processes, with a "big" data-driven clinical research and development loop to bring relief to patients in communities across the country. Through our GBS PR subsidiary, we are developing and globally distributing our GrowBLOX ™ suite of cultivation and growing chambers. To learn more about GrowBLOX Sciences, Inc., go to: http://growblox.com
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GrowBLOX is a registered trademark of GrowBLOX Sciences, Inc.
Contact Information
Corporate:
GrowBLOX Sciences, Inc.,
3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Liz Bianco Publicity Director, liz@gbsciences.com, http://growblox.com
Investors: John Poss, j.poss@gbsciences.com
SOURCE GrowBLOX Sciences, Inc.
Related Links
http://kylekushman.com
http://growblox.com
GrowBLOX Sciences, Inc. Announces Exclusive Rights To Kyle Kushman's Cannabis Brands, Strains And Genetics In The State Of Nevada
LAS VEGAS, June 7, 2016 /PRNewswire/ -- GrowBLOX Sciences, Inc. (OTCQB: GBLX) announces the execution of an agreement with Kyle Kushman, Kushman Brands and Genetics LLC, and its affiliate Karma Consulting (collectively, "Kushman"). Pursuant to the agreement, GrowBLOX and its subsidiary GB Sciences Nevada, LLC (dba "Cultivation Labs") will have exclusive rights in Nevada to Kushman's cannabis brands, strains and genetics. Kushman also will advise GB Sciences' Cultivation Labs on the expansion of its cannabis cultivation facility in Las Vegas, as well as operating processes and procedures based on Kushman's methods and unique Veganic growing techniques.
Kyle Kushman (http://kylekushman.com/) is one of the most well-known and award winning cannabis cultivators in the world. He has won 13 Cannabis Cup High Times awards, the "Oscar" of the Cannabis industry. Kyle brings all of his diverse and award-winning strains to GB Sciences' Cultivation Labs, including Strawberry Cough, Cherry Cough, Adonai OG, Silverback Grape Ape, Starberry, KK Stardawg and Jurassic Haze strains. Kyle's Veganic method of growing has been described as the next step in "organic" cultivation and has been shown to produce some of the cleanest and most efficacious cannabis in the marketplace.
GrowBLOX Founder and Chief Innovation Officer, Craig Ellins said, "The cannabis world knows about the amazing marijuana products created by Kyle Kushman, particularly his 'Vegamatrix' line of vegan and organic nutrients – the only nutrients capable of nurturing the cleanest and purest cannabis possible. When one combines Kushman's 30 years of experience and expertise and demonstrably superior nutrients with our innovative tissue culturing technology, the result can only be the best and most consistent pesticide free, natural medical marijuana products ever produced from the cannabis plant."
GrowBLOX CEO, John Poss said, "This is a major win for medical marijuana patients in Nevada and a homerun for our shareholders. The exclusive on his brands together with his cultivation design expertise and his Vegamatrix nutrients will clearly give us a competitive advantage in Nevada. The eight strains he brings will complement perfectly the over 20 strains that GB Sciences has developed to offer a wide variety of treatment options to marijuana patients. This deal positions us perfectly in the medical cannabis market, but also gives us a strong position in the soon to come recreational market, which is expected to be created by a proposition vote in November of this year."
Kushman said, "I feel that my expertise paired with the labs and systems put in place by GrowBLOX is a dream come true. Using artisanal techniques to take medical cannabis to its highest level, we are going to produce the highest quality Veganic cannabis for Nevada medical marijuana patients."
GrowBLOX Chief Science Officer, Dr. Andrea Small-Howard, said, "The Kushman brands and genetics are among the best-known in the world among both personal and commercial growers of the cannabis plant. Growing Kushman strains in our Cultivation Labs facility in Las Vegas and using their proven cultivation methods should ensure the superior productivity, high potency and clean test results afforded by the organic nutrients in the Vegamatrix line."
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc. (GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. The Company has leading technology and cannabis industry processes, with a "big" data-driven clinical research and development loop to bring relief to patients in communities across the country. Through our GBS PR subsidiary, we are developing and globally distributing our GrowBLOX ™ suite of cultivation and growing chambers. To learn more about GrowBLOX Sciences, Inc., go to: http://growblox.com
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GrowBLOX is a registered trademark of GrowBLOX Sciences, Inc.
Contact Information
Corporate:
GrowBLOX Sciences, Inc.,
3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Liz Bianco Publicity Director, liz@gbsciences.com, http://growblox.com
Investors: John Poss, j.poss@gbsciences.com
SOURCE GrowBLOX Sciences, Inc.
Related Links
http://kylekushman.com
http://growblox.com
GB Sciences Seeks Patent for Cannabis-based Treatment for Bowel Diseases
https://ibdnewstoday.com/2017/02/07/gb-sciences-seeks-patent-for-marijuana-based-therapy-for-inflammatory-bowel-diseases/
Growblox Sciences Announces Patent Application for Treatments of Parkinson's Disease, Alzheimer's Disease, Huntington's Disease and Dementia
http://www.prnewswire.com/news-releases/growblox-sciences-announces-patent-application-for-treatments-of-parkinsons-disease-alzheimers-disease-huntingtons-disease-and-dementia-300343440.html
About Growblox Sciences
Growblox Sciences, Inc. (Growblox) is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. The Company seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. Growblox intends to conduct its business operations, through its subsidiaries, in approximately three operating units, which include Solutions, Sciences and Product divisions.
GB Solutions
The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB.
GB Sciences
GB Sciences’ Drug Development program endeavors to provide novel cannabinoid therapies to patients with critically unmet needs. Starting with certified, cannabis plant-derived ingredients from the GrowBLOX™ technology suite, GB Sciences tests proprietary ratios of active ingredients in an accelerated drug development program.
GB Products
The GBLX line of products is the signature collection of cannabinoid therapies developed and produced by GrowBlox Sciences. Infused with certified-active ingredients derived from cannabis plants grown using the GrowBLOX system. This line of product features proprietary cannabinoid and terpenoid blends that are being extensively studied for optimal efficacy.
GB Sciences Unique Retail Solution – The Apothecary
GB Sciences has designed a unique retail environment for cannabinoid therapy providers to deliver exceptional patient care. The Apothecary by GB Sciences combines a simple, clean and clinical design with cutting edge bio-metrics and patient verification to deliver a pleasant and safe customer experience.Highly trained and certified ApotheCAREians will work with patients to determine their medical needs, identify therapeutic products, install GB Sciences’ app on their hand-held devices, and demonstrate how to place orders.
The Micro Apothecary is a self-service vending kiosk. The interactive LED monitors display essential product and patient safety information and doubles as the touch screen interface that allows you to create a new patient profile or sign in to an existing account.
The Apothecary will have a mobile app as a powerful tool for building a strong patient- dispensary relationship.
Check out these videos outlining the features of “The Apothecary” and the proposed mobile app and read more about GBLX’s retail solutions at http://growblox.com/gbs-production/distrubution.html
GBLX MJ PHARMACEUTICAL COMPANY
Name Change due any day now...really gonna take off!
GB SCIENCES is a medical marijuana company not a recreational Mj Company the drop in the last few days won't last. This stock will surge soon. Small Float cash on hand. And $20 Million in revenue coming this year from Vegas Medical Facility. California, Texas and Pennsylvania will be host to GB Sciences Medical Marijuana cultivation turning in near $20 Million a year in revenue in each location. . The company has stated the revenue will offset the medical pipeline that company has.
CNBX 360 Million Market Cap
CBIS 209 Million Market Cap
OWCP 230 Million Market Cap
AXIM 441 Million Market Cap
GBLX 40 Million Market Cap
GB Sciences should have a major up swing in PPS in the coming weeks & months to be more in line with there peers. The scientific Team is second to none in the field.
Anything under .40 cents is a steal. This could move over 100%+ on Mile Stone updates. $1.50 Target by year end.
https://www.greenrushdaily.com/2017/01/18/investment-experts-predict-explosive-year-cannabis/
According to Robinson, there have been 64 cannabis companies that have had stock growth of over 1,000%. But he said it gets it even better.
Eleven of those 64 companies saw their stocks rise above 10,000% growth. Stocks in 5 of those companies rose more than 25,000%. Three of them went over 50,000%. And one cannabis company’s stock increased by more than 130,000%.
GBLX has 1000%+ Increase in Share price potential.
GBLX NEXT BIG MJ PLAY RESEARCH & DEVELOPMENT
Name Change due any day now...really gonna take off
GB SCIENCES is a medical marijuana company not a recreational Mj Company the drop in the last few days won't last. This stock will surge soon. Small Float cash on hand. And $20 Million in revenue coming this year from Vegas Medical Facility. California, Texas and Pennsylvania will be host to GB Sciences Medical Marijuana cultivation turning in near $20 Million a year in revenue in each location. . The company has stated the revenue will offset the medical pipeline that company has.
CNBX 360 Million Market Cap
CBIS 209 Million Market Cap
OWCP 230 Million Market Cap
AXIM 441 Million Market Cap
GBLX 40 Million Market Cap
GB Sciences should have a major up swing in PPS in the coming weeks & months to be more in line with there peers. The scientific Team is second to none in the field.
Anything under .40 cents is a steal. This could move over 100%+ on Mile Stone updates. $1.50 Target by year end.
https://www.greenrushdaily.com/2017/01/18/investment-experts-predict-explosive-year-cannabis/
According to Robinson, there have been 64 cannabis companies that have had stock growth of over 1,000%. But he said it gets it even better.
Eleven of those 64 companies saw their stocks rise above 10,000% growth. Stocks in 5 of those companies rose more than 25,000%. Three of them went over 50,000%. And one cannabis company’s stock increased by more than 130,000%.
GBLX has 1000%+ Increase in Share price potential.
GBLX
Name Change due any day now...really gonna take off
GB SCIENCES is a medical marijuana company not a recreational Mj Company the drop in the last few days won't last. This stock will surge soon. Small Float cash on hand. And $20 Million in revenue coming this year from Vegas Medical Facility. California, Texas and Pennsylvania will be host to GB Sciences Medical Marijuana cultivation turning in near $20 Million a year in revenue in each location. . The company has stated the revenue will offset the medical pipeline that company has.
CNBX 360 Million Market Cap
CBIS 209 Million Market Cap
OWCP 230 Million Market Cap
AXIM 441 Million Market Cap
GBLX 40 Million Market Cap
GB Sciences should have a major up swing in PPS in the coming weeks & months to be more in line with there peers. The scientific Team is second to none in the field.
Anything under .40 cents is a steal. This could move over 100%+ on Mile Stone updates.
$1.50 Target by year end.
https://www.greenrushdaily.com/2017/01/18/investment-experts-predict-explosive-year-cannabis/
According to Robinson, there have been 64 cannabis companies that have had stock growth of over 1,000%. But he said it gets it even better.
Eleven of those 64 companies saw their stocks rise above 10,000% growth. Stocks in 5 of those companies rose more than 25,000%. Three of them went over 50,000%. And one cannabis company’s stock increased by more than 130,000%.
GBLX has 1000%+ Increase in Share price potential.
GBLX
Name Change due any day now...really gonna take off
GB SCIENCES is a medical marijuana company not a recreational Mj Company the drop in the last few days won't last. This stock will surge soon. Small Float cash on hand. And $20 Million in revenue coming this year from Vegas Medical Facility. California, Texas and Pennsylvania will be host to GB Sciences Medical Marijuana cultivation turning in near $20 Million a year in revenue in each location. . The company has stated the revenue will offset the medical pipeline that company has.
CNBX 360 Million Market Cap
CBIS 209 Million Market Cap
OWCP 230 Million Market Cap
AXIM 441 Million Market Cap
GBLX 40 Million Market Cap
GB Sciences should have a major up swing in PPS in the coming weeks & months to be more in line with there peers. The scientific Team is second to none in the field.
Anything under .40 cents is a steal. This could move over 100%+ on Mile Stone updates.
$1.50 Target by year end.
https://www.greenrushdaily.com/2017/01/18/investment-experts-predict-explosive-year-cannabis/
According to Robinson, there have been 64 cannabis companies that have had stock growth of over 1,000%. But he said it gets it even better.
Eleven of those 64 companies saw their stocks rise above 10,000% growth. Stocks in 5 of those companies rose more than 25,000%. Three of them went over 50,000%. And one cannabis company’s stock increased by more than 130,000%.
GBLX has 1000%+ Increase in Share price potential.
BOTTOM!
There, it's been called...
And I honestly hope it is. This ticker just needs more publicity on the other boards.
It should get more eyes once the name changes and the corporate mission statement is released.
Best of luck!
GB Sciences matching cannabis strains with disease targets
GBLX
GBX01
Cancer Treatments
Reduces Nauseu
Increases Appetite
GBX02
Cardio- protection
Fights ischemia
Increases circulation
GBX03
Metabolic Syndrome
Lowers blood sugar
Suppresses appetite
GBX04
Pain Management
Reduces aches & pains
Reduces Chronic pain
GBX05
Neurological Disorder
induces sleep
relives anxiety
Protects Nerves
Lessens spasms Fights psychosis
Combats depression
Reduces epileptic seizures
GBX06
Inflammation
Relieves psoriasis
Decrease gastric inflammation
GBX07
Compromised Immune System
Immunostimulant
fights nausea
reduces wasting syndrome
Is the bottom in, or do you think it will hit .10?
Extremely volatile stock
Looks like it may drop more?
Too many weak hands at this point?
People are scared of the share count.
So I will set my order at .10
Up listing may never happen...too high of share count!
Could end up doing a reverse split to increase PPS?
Keep your head up longs!
Still has a chance to become cash positive!
I'm right there along with you. The lack of news that tells the story is something they are good at. I do like the contracts, I do like the numbers, I do like the positive motivation and the way they had cleaned up the books to uplist and move onto bigger and better projects...what I don't like is the lack of names of the companies they are working for, and no way to actually verify the millions of dollars in awaiting contracts. The audited financials will be a huge help, and actually seeing profits will make this thing really take off.
Just like you, I sold a significant portion on the run up, and am looking to get back in around .40 Or so I hope to pick up there.
Best of Luck!
JJAAMMAANN
$6.00 - $8.00 price target
Going to be interesting over the coming weeks/months...
Lots going on behind the scene as well as the request to uplist.
Yes, Remoxy/Pain...3 time Fail
We do know a deal is coming...
May not be the deal that was speculated by Spyder, but none-the-less a deal is coming.
TY Tonecee,
Do you have the date they applied for BTD?
Also, is the 60 days calendar days, or business days?
Exciting either way!
Thanks once again,
JJAAMMAANN
TY Grip it,
May grab a few shares today...looks very appealing with lots of potential. I am surprised that a big pharma has not thrown an offer their way yet. Wouldn't be surprised to see it soon.
Best of Luck!
Just came across this ticker.
Sorry for the question, but what is BTD Approval?
I have read through about 200 threads, and see several mentions of it, but don't know what it means.
Thanks for any help.
JJAAMMAANN
16B or 20B shares are significant, but with FDA approval, it may not matter once financials are released and BIEL signs a deal with a big marketing company, gets endorsements, moves into pharmacies across the country. With FDA approval, along comes DOCTOR RECOMMENDATIONS. Doctors don't recommend things not FDA approved, but with the approval, they will recommend Actipatch by name.
By the way, NOKIA has over 5B Shares and is trading at $5.00
In comparison, that would be 20B at $1.25
Rough numbers...not exact numbers.
I have bought in BIEL in the past, but currently do not own any shares....May take a position on Tuesday
Good Luck everyone!
Snupdawg, Welcome to FTE
I wouldn't say you are late to the party at this point, not sure when the up-listing will take place, but that is where the legitimate accumulation will start from the big boys. The details of the up-listing are a little fuzzy at this point, but the Business background of FTE is legit.
Think of them as a quasi CISCO/NOKIA type company specializing in Fiber Optics and Networking. Business is growing quickly, and there are over 100 Million in contracts still to be fulfilled.
I'm sure there will be dips, but definitely looks like it will continue to rise from these levels.
Good Luck & Happy Trading!
FTE Making Strides in the right direction!
Uplisting in 2017 should be a no brainer!
Good Luck everyone!
Sell/Borrow, Borrow/Sell...
What is the difference?
They SELL shares to LP...LP Gives them Money for said shares....dumps shares...gains profit.
Technically not borrowed money...DIE.Lution of the Company.
Even worse...you are right, I was trying to be nice about it.
ELTP is going to dump all their shares until they need to do a reverse split and increase authorized shares.
DIE~LUTION = NOT GOOD! :(
JMHO
35% left of $40 MILLION to borrow.
It is pretty simple really,
Again, if you are long, I'm not trying to offend...just offer up my opinion.
ELTP knows that the Lincoln Park Deal is nearing completion...Better believe if they can't extend them, they are gong to force them to take millions and millions more in shares...to the tune of 800,000 shares per day worth...lots of days between now then???
ELTP down $0.04 in a Month...
So, $0.178 down to $0.138
And I am living in the pipe dream?
What is a few more pennies to get it to $0.10?
Just a few less believers, and it will be there...TRENDING DOWN!
Not that hard to fathom...TEN CENTS is way closer than ONE DOLLAR.
JMHO
Good Point Steve, why would I want to buy at $0.10?
Just as NASDAQ states, One or Two more...may cause a little pop in the price. But trending down at the time being...
Set your buy at 10 CENTS...Hopefully that will be the bottom.
Total speculation on my part, but looks like it may be a good entry point.
Hey, if your long...I'm not trying to offend.
Just a trader looking at BIOPHARMS.
ELTP was promising a while back until FDA said NO WAY,
But there is always a chance...VERY BAD IN THE LOAN DEPARTMENT!
Financials saying money earned will be a pop in the price...but won't touch the Debt that ELTP owes.
JMHO
Exactly my point...MAYBE!
But even if your ideas hit...still have to pay the $35 MILLION BORROWED!
Better be some prenominal drug launches...not those 100 million dollar ones that need to be partnered, and split profits of a small market share...you know the typical ELTP partnerships...this is why they still have to borrow money to operate!
How much money is being generated on any of these "First Ever's"?
I didn't read anywhere in the Quarterly/Annual that any of those you mentioned are garnering any income?
When is the FDA going to approve?
When is the PDUFA?
When do the sales begin?
Lots of IF'S...
Show me the money?
Until financials get better than the money($40~MILLION) they keep borrowing from Lincoln Park and the money ($1~MILLION+12*INTEREST) they have to keep borrowing from NasaRat, the PPS will not go up.
Need positive FINANCIAL news...not If's, Maybe's, and Almosts...
JMHO
It is the company ELTP that is forcing Lincoln Park to buy the shares...if anyone should be upset, it is Lincoln Park.
They too want the price to go below $0.10 so ELTP can't force them to buy any more worthless shares!
Of course the Lincoln Park Deal will be extended,
How else will ELTP and NasaRat pay the light bills until ELTP goes under?
JMHO
Looks like Lincoln Park owns ELTP...????
Ten Cents $0.10 by End of Week!
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeee
the Company issued 1,928,641 shares of common stock to Lincoln Park pursuant to the Purchase Agreement as consideration for its commitment to purchase additional shares of common stock under that agreement and the Company is obligated to issue up to an additional 1,928,641 commitment shares to Lincoln Park pro rata as up to $40 million of common stock purchased by Lincoln Park. Through December 31, 2016, we have sold to Lincoln Park an aggregate of 89.7 million shares under the Purchase Agreement for aggregate gross proceeds of approximately $24.0 million. In addition, we have issued an additional 1.2 million Commitment Shares.
The Company, from time to time and at the Company’s sole discretion but no more frequently than every other business day, direct Lincoln Park to purchase (a “Regular Purchase”) up to 500,000 shares of common stock on any such business day, increasing up to 800,000 shares, depending upon the closing sale price of the common stock, provided that in no event shall Lincoln Park purchase more than $760,000 worth of common stock on any single business day.
With so many promising ANDAs, why is ELTP still trending downward?
Does retail not agree with you sentiments?
Seems like a no brainer to accumulate at these low prices...
Oh wait, it looks to be going lower...
I'll set a buy at 10 cents...start to accumulate there.
LOTS of IFs on ELTP...if, If, iF, IF...maybe, Maybe, mAybe, maYbe, mayBe, maybE,...some day, ELTP?
Good Luck!
FTE Networks Retains MBS Value Partners as Its Investor Relations and Corporate Communications Firm
NAPLES, FL.-- (MARKETWIRED)January 5, 2017 FTE Networks, Inc. (OTCQX: FTNW), a leading network infrastructure solutions provider in technology and communications, today announced that it has engaged New York-based MBS Value Partners (MBS) as its investor relations and corporate communications firm. Effective immediately, MBS will advise the Companys senior management on investor relations and corporate communications strategy, messaging, and outreach.
FTE Networks has been growing powerfully and is poised to capitalize on many promising opportunities, said Michael Palleschi, FTE Networks Chairman and CEO. We have a strong contract pipeline and a growing market footprint, both nationally and globally. And, we have in place an outstanding management team. MBS will help us deepen our connection to institutional investors and provide greater exposure for our world-class products and services for Fortune 500 companies.
The MBS team representing FTE will be led by Monique Skruzny, partner and co-founder of MBS, and Jon Elsen, MBSs senior counsel for corporate communications. Joining Skruzny and Elsen on the FTE account are Senior Associate Robert Goetze and Alex Arzeno, Director of Market Intelligence.
About FTE Networks
FTE Networks is on the leading edge of network transformation, helping communications service providers, government and enterprise customers evolve their networks to meet advancing technology requirements via network infrastructure, and edge computing solutions to quickly enhance service innovation and deliver new revenue streams. With a focus on smart design, open architectures and consistent standards, along with expertise in building, operating, and maintaining networks, FTE solves complex network and system challenges that reduce costs and deployment time to accelerate delivery and optimize performance of network infrastructure. Operating five (5) industry segments; Data Center Infrastructure, Fiber Optics, Wireless Integration, Network Engineering, and Compute to the Edge, FTE Networks is headquartered in Naples, Florida, with offices throughout the United States and Europe. For more information, please visit: www.ftenet.com.
About MBS Value Partners
Headquartered in New York City, with a presence in Boston, Buenos Aires and So Paulo, MBS Value Partners is an investor relations and corporate communications firm that provides senior level advisory work and customized investor relations, financial media and corporate communications programs for a roster of domestic and international clients. MBS serves the technology, business services, industrials, clean technology and biotechnology verticals in the U.S. For information on the firms approach, services and leadership team, please visit the MBS Value Partners website at www.mbsvalue.com.
Contacts:
Investor Relations:
Robert Goetze: (212) 897 9667, robert.goetze@mbsvalue.com
Media:
Jon Elsen: (914) 305 6981, jon.elsen@mbsvalue.com
They formed the strategic advisory board...what is the advice?
It really is about time for an update! Been quiet for too long. Need to hear of some of the positive things going on and status of current contracts.
Is today the day we go back above $5?
FTE Networks Forms Strategic Advisory Board, Appoints Initial Group of Advisors
Senior-Level Leaders in Advanced Technology, Cloud, and Open Compute
Will Help FTE Maximize Impact of Multi-Edge Computing Services
NAPLES, Fla.--(December 7, 2016 -- InvestorsHub Newswire--) - FTE Networks, Inc. (OTCQX:FTNW) ("FTE" or the "Company"), a leading network infrastructure solutions provider to the technology and communications industry, today announced it has formed a Strategic Advisory Board to provide senior counsel to the company on opportunities to evolve and advance the deployment of its disruptive multi-edge computing services.
External Members of FTE Networks Multi-Edge Computing Strategic Advisory Board are:
John Morgan, Telecom and Social Media Industry Veteran
David Kalinske, Chief of Staff for A3 by Airbus Group, the Silicon Valley outpost of Airbus Group
Eric Salzman, Sr. Managing Director, Monarch Capital Group, LLC
Chairman of the Multi-Edge Computing Strategic Advisory Board and COO of FTE Networks, Lynn Martin, said, With new game-changing technologies in design and development, the time is right to begin thinking more broadly about maximizing the impact of our new multi-edge computing services and identifying the range of opportunities and markets available to us.
The establishment of our Strategic Advisory Board represents our commitment to build on the companys recent momentum and pursue smart, strategic growth opportunities, said Michael Palleschi, FTE Networks (FTNW) Chairman of the Board and Chief Executive Officer. Each member brings extensive cloud and open compute expertise, and will be a tremendous asset as we develop our next generation business of data center and multi-edge computing services.
Background on Advisory Board Members
John Morgan. Mr. Morgan is currently working with operators to improve network coverage and capacity to make the world more open and connected. Morgan has over twenty-five years in the Communications and IT Industries and is currently supporting operators with the adoption of open source hardware and software in their networks through the Open Compute Project (OCP) and Telecom Infrastructure Project (TIP) initiatives. Prior to his current work, Morgan was global technical lead for legacy network migrations at Accenture where he worked with operators on product rationalization and simplification, copper to fiber migration platform implementations, and decommissioning strategies for copper and central office equipment. Prior to Accenture, he held executive positions with several software start-up firms in the communications industry, as well as with leading operators, such as Verizon, Level 3 Communications, and Genuity. His background includes work in network planning and engineering, product management, OSS/BSS development, finance, and operations. He completed his undergraduate work in Accounting at the College of William and Mary and received his MS in Information and Telecommunications Systems from the Johns Hopkins University.
David Kalinske. Mr. Kalinske is the Chief of Staff for A3 by Airbus Group and former Aide to two U.S. Presidents, President George W. Bush and President Barack Obama. In his previous role, he was the recipient of the Defense Superior Service Medal for superior meritorious service in the position of significant national responsibility as Aide to the President of the United States. He also served as a research engineering leader with Lockheed Martin Aeronautics supporting Advanced Development programs, also known as The Skunk Works, and founded Global Hybrid Company, an airborne logistics provider utilizing the revolutionary Hybrid Airship. A TOPGUN graduate and a Marine Corps fighter squadron Commanding Officer (CEO), he was selected via scholarship into the Harvard University, Kennedy School of Government, National Security Fellow program with a focus in the study of cybersecurity policy.
Eric Salzman. Mr. Salzman has 20 years of experience working with communications and software companies with a focus on driving operational and financial excellence. He is currently a Senior Managing Director at Monarch Capital Group, LLC, a boutique investment bank and money management firm and serves as an independent director on several public and private technology company boards including 8x8, Inc., ASG Technologies, Sorenson Communications and FragranceNet.com. Prior to 2011, Mr. Salzman spent eight years at Lehman Brothers as a Managing Director in the Private Equity and Principal Investing Group, as well as a Managing Director in the Global Trading Strategies Division, including three years managing the operational and financial restructuring of dozens of companies within the Lehman Bankruptcy. Prior to Lehman Brothers, Mr. Salzman was a senior investment professional focused on the technology and communications industry at a multi-strategy hedge fund and at two growth-oriented private equity funds. Mr. Salzman began his career in the M&A Group at CS First Boston. Mr. Salzman graduated with a B.A. Honors from the University of Michigan and received his MBA from Harvard University.
For complete bios please see company website http://ir.ftenet.com/.
About FTE Networks, Inc.
FTE Networks is on the leading edge of network transformation, helping communications service providers, government and enterprise customers evolve their networks to meet advancing technology requirements via network infrastructure, and edge computing solutions to quickly enhance service innovation and deliver new revenue streams. With a focus on smart design, open architectures and consistent standards, along with expertise in building, operating, and maintaining networks, FTE solves complex network and system challenges that reduce costs and deployment time to accelerate delivery and optimize performance of network infrastructure. Operating five industry segments Data Center Infrastructure, Fiber Optics, Wireless Integration, Network Engineering, and Compute to the Edge FTE Networks is headquartered in Naples, Florida, with offices throughout the United States and Europe. For more information, please visit: www.ftenet.com.
Forward-Looking Statements
This release may contain forward-looking statements relating to the business of FTE. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. These statements involve risks and uncertainties that may cause actual results to differ materially from those anticipated, believed, estimated or expected. These risks and uncertainties are described in detail in our filings with the Securities and Exchange Commission. Forward-looking statements are based on FTE's current expectations and beliefs concerning future developments and their potential effects on FTE. There is no assurance that future developments affecting FTE will be those anticipated by FTE. FTE undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as required under applicable securities laws.
Contacts:
FTE Networks, Inc.
999 Vanderbilt Beach Rd., Suite 601
Naples, FL 23108
(877) 850-4308
ir@ftenet.com
OTCQX:FTNW
Investor Relations:
Natalya Rudman
Crescendo Communications, LLC
(212) 671-1020, Ext: 304
ftnw@crescendo-ir.com